Citigroup Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $160
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst David Hoang maintains a Neutral rating on Sarepta Therapeutics (NASDAQ:SRPT) but lowers the price target from $176 to $160.
August 08, 2024 | 7:06 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Citigroup analyst David Hoang maintains a Neutral rating on Sarepta Therapeutics but lowers the price target from $176 to $160.
The lowered price target from $176 to $160 by Citigroup suggests a less optimistic outlook for Sarepta Therapeutics, which could negatively impact investor sentiment and short-term stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100